Table 2.
Adverse events: Baseline vs. week 4 (end of study).
| Queried adverse events (AE) | Baseline (# reporting/10) | Week 4 (# reporting/10) | Note |
|---|---|---|---|
| Diarrhea | 0 | 0 | – |
| Constipation | 0 | 0 | – |
| Dry Mouth | 0 | 0 | – |
| Nausea | 1 | 0 | Resolved since baseline |
| Palpitations | 0 | 0 | – |
| Dizziness | 0 | 1 | New since baseline |
| Chest Pain | 0 | 0 | – |
| Rash | 0 | 0 | – |
| Perspiration | 0 | 0 | – |
| Itching | 0 | 0 | – |
| Dry skin | 1 | 0 | Resolved since baseline |
| Headache | 0 | 0 | – |
| Tremors | 0 | 0 | – |
| Poor coordination | 1 | 0 | Resolved since baseline |
| Blurred vision | 1 | 0 | Resolved since baseline |
| Tinnitus | 2 | 1 | No change from baseline |
| Difficulty urinating | 0 | 0 | – |
| Painful urination | 0 | 0 | – |
| Frequent urination | 2 | 1 | No change from baseline |
| Menstrual irregular | 3 | 3 | No change from baseline |
| Difficulty sleeping | 1 | 3 | Two new since baseline |
| Hypersomnia | 1 | 0 | Resolved since baseline |
| Loss of libido | 1 | 0 | Resolved since baseline |
| Anxiety | 2 | 2 | No change from baseline |
| Poor concentration | 2 | 1 | New since baseline |
| Malaise | 0 | 0 | – |
| Restlessness | 1 | 1 | No change from baseline |
| Fatigue | 2 | 1 | No change from baseline |
| Decreased energy | 0 | 3 | Three new since baseline |